Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Verona Pharma To Present Phase 3 ENHANCE COPD Analyses At ERS 2025, Highlighting Ohtuvayre (Ensifentrine) Benefits On Lung Function, Exacerbations, Symptoms And Quality Of Life

Author: Benzinga Newsdesk | September 16, 2025 05:13am

Posted In: VRNA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist